"On December 1, people throughout the world observe World AIDS Day, an opportunity for the global community to honor those living with HIV; the families, friends, caregivers, and communities who support them; and those who have lost their lives to"...
ATRIPLA® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
DOSAGE AND ADMINISTRATION
Adults and pediatric patients 12 years of age and older with body weight at least 40 kg (at least 88 lbs)
The dose of ATRIPLA is one tablet once daily taken orally on an empty stomach. Dosing at bedtime may improve the tolerability of nervous system symptoms.
Because ATRIPLA is a fixed-dose combination, it should not be prescribed for patients requiring dosage adjustment such as those with moderate or severe renal impairment (estimated creatinine clearance below 50 mL/min).
When ATRIPLA is administered with rifampin to patients weighing 50 kg or more, an additional 200 mg/day of efavirenz is recommended [See DRUG INTERACTIONS, Table 4, and CLINICAL PHARMACOLOGY, Table 5].
Dosage Forms And Strengths
ATRIPLA is available as tablets. Each tablet contains 600 mg of efavirenz, 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (tenofovir DF, which is equivalent to 245 mg of tenofovir disoproxil). The tablets are pink, capsule-shaped, film-coated, debossed with “123” on one side and plain-faced on the other side.
Storage And Handling
ATRIPLA tablets are pink, capsule-shaped, film-coated, debossed with “123” on one side and plain-faced on the other side. Each bottle contains 30 tablets (NDC 155840101-1) and silica gel desiccant, and is closed with a child-resistant closure.
Store at 25 °C (77 °F); excursions permitted to 15–30 °C (59–86 °F) [See USP Controlled Room Temperature].
- Keep container tightly closed.
- Dispense only in original container.
- Do not use if seal over bottle opening is broken or missing.
Bristol-Myers Squibb and Gilead Sciences, LLC. Revised: January 2015
Last reviewed on RxList: 2/13/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Atripla Information
Atripla - User Reviews
Atripla User Reviews
Now you can gain knowledge and insight about a drug treatment with Patient Discussions.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.